Gregory Riely, MD, PhD

Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.

Closing out their review of the second patient scenario, panelists define treatment options for NSCLC with both EGFR mutation and PD-L1 expression.

Expert oncologists consider how they would approach molecular testing in a 73-year-old Asian woman diagnosed with advanced non–small cell lung cancer.

Focusing on second-line treatment options for EGFR-mutated advanced NSCLC, panelists review the use of mobocertinib and amivantamab, respectively.

Experts briefly reflect on optimal frontline treatment strategies for a patient who presents with EGFR-mutated advanced non–small cell lung cancer.

Centering discussion on a 57-year-old man with advanced NSCLC, panelists consider molecular testing strategies and the subsets of EGFR mutation.

A brief reflection on optimal patient education strategies, specifically regarding biomarker testing, in the setting of non–small cell lung cancer.

Closing out their discussion on NSCLC biomarker testing assay selection, panelists consider the optimal use of these assays in their own patients.

Expert oncologists provide a comprehensive review of available biomarker testing assays utilized in patients diagnosed with non–small cell lung cancer.

Gregory Riely, MD, PhD, and Tarek Mekhail, MD, detailed the use of mobocertinib of platinum-pretreated patients with metastatic non–small cell lung cancer.